Loading...
XSHG600812
Market cap1.20bUSD
Dec 24, Last price  
5.36CNY
1D
0.19%
1Q
11.20%
Jan 2017
-14.38%
Name

North China Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600812 chart
P/E
1,787.42
P/S
0.86
EPS
0.00
Div Yield, %
5.91%
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
1.89%
Revenues
10.12b
-3.62%
4,124,209,7383,971,939,3483,598,124,4494,240,587,1424,910,957,1074,882,522,14510,286,643,42112,136,745,65311,125,706,15612,438,143,7029,400,972,6957,902,502,2978,082,462,7807,709,121,8769,213,775,28410,880,767,82411,492,504,16310,384,575,26010,499,947,06510,120,201,384
Net income
5m
59,147,413038,943,17560,539,604269,100,6560241,831,473124,769,89317,797,22713,655,28641,618,16762,848,31754,415,07618,759,714150,646,419153,445,29297,323,76135,382,06504,890,347
CFO
1.02b
+1.98%
310,389,261224,170,895597,119,177664,370,9711,085,521,9351,011,129,1700227,598,5360090,562,752122,495,0450287,250,352774,325,700732,966,510752,146,7631,050,241,9931,004,390,7941,024,266,655
Dividend
Jul 18, 20240.01 CNY/sh

Profile

North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.
URL
http://www.ncpc.com
IPO date
Jan 14, 1994
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
10,120,201
-3.62%
10,499,947
1.11%
10,384,575
-9.64%
Cost of revenue
8,843,372
9,298,809
9,313,280
Unusual Expense (Income)
NOPBT
1,276,829
1,201,138
1,071,295
NOPBT Margin
12.62%
11.44%
10.32%
Operating Taxes
109,148
113,707
99,523
Tax Rate
8.55%
9.47%
9.29%
NOPAT
1,167,682
1,087,431
971,772
Net income
4,890
 
35,382
-63.64%
Dividends
(516,223)
(102,944)
(48,933)
Dividend yield
5.56%
0.94%
0.24%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,467,710
8,506,073
10,149,049
Long-term debt
4,679,180
2,955,852
3,954,210
Deferred revenue
36,805
40,062
44,436
Other long-term liabilities
900
900
900
Net debt
7,938,988
8,861,206
7,836,440
Cash flow
Cash from operating activities
1,024,267
1,004,391
1,050,242
CAPEX
(623,035)
Cash from investing activities
(882,344)
Cash from financing activities
(704,143)
314,576
FCF
2,756,470
1,388,706
1,478,188
Balance
Cash
988,276
1,682,737
5,304,983
Long term investments
1,219,626
917,981
961,835
Excess cash
1,701,892
2,075,721
5,747,589
Stockholders' equity
2,391,040
2,349,006
3,138,110
Invested Capital
14,453,953
15,122,450
17,585,824
ROIC
7.90%
6.65%
5.61%
ROCE
7.90%
6.98%
5.17%
EV
Common stock shares outstanding
1,630,116
1,715,730
1,702,495
Price
5.70
-10.94%
6.40
-46.31%
11.92
15.84%
Market cap
9,291,660
-15.38%
10,980,674
-45.89%
20,293,742
20.93%
EV
18,185,754
20,770,131
29,061,932
EBITDA
2,154,875
1,980,158
1,774,528
EV/EBITDA
8.44
10.49
16.38
Interest
511,901
599,391
642,691
Interest/NOPBT
40.09%
49.90%
59.99%